BioDelivery Sciences International, Inc. — Cyborg Score 5/10

Mixed
Specialty pharmaceuticals for chronic pain management

Strategic Profile

BDSI competes in the specialty pharma space with differentiated drug-delivery technologies rather than first-to-market compounds. The company has secured patent protection for its key asset Belbuca with exclusivity extending to 2032 against generic competition. The company remains focused on expanding its portfolio and improving patient access to chronic pain treatments across various therapeutic modalities.

Cyborg Score Rationale

BDSI operates in a mature market with established products (Belbuca, Symproic) and proprietary drug-delivery technology providing differentiation. However, the company faces competitive pressures from larger pharma players, limited pipeline visibility in recent data, and historically modest financial performance. Patent protection through 2032 provides medium-term revenue stability.

Top Insights

  • BEMA technology provides differentiated buccal-delivery mechanism for chronic pain medications, creating competitive moat vs. generic alternatives
  • Patent litigation win in December 2021 against Alvogen secured market exclusivity for Belbuca through 2032, protecting near-term revenue
  • Company maintains public listing status as of June 2026, despite prior announcement of Collegium acquisition in February 2022—deal status unclear from available data
  • Narrow product portfolio (two main products: Belbuca and Symproic) concentrates revenue dependency and limits diversification

Named Competitors

  • Xtampza ER / Collegium Pain Portfolio — Extended-release opioid pain medications
  • Extended-release opioid products — Oxycontin and other chronic pain therapeutics
  • Generic buprenorphine and naldemedine — Over-the-counter and generic pain management alternatives

Recent Developments

  • (February 2022) Merger agreement announced with Collegium Pharmaceutical for $5.60 per share ($604 million equity value); expected Q1 2022 close—status as of June 2026 unclear
  • (December 2021) Prevailed in patent litigation against Alvogen, securing Belbuca exclusivity through 2032
  • (October 2021) Appointed John Golubieski as Chief Financial Officer

Open the full interactive BioDelivery Sciences International, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →